Immatics N.v. · NASDAQ:IMTX
Immatics — Investor Presentation (April 2021)
35 slides from Immatics's investor presentation, Apr 1, 2021
Slide 1: Unlocking Immunotherapies for Solid Cancer Patients
© Immatics. Not for further reproduction or distribution. Unlocking Immunotherapies for Solid Cancer Patients Immatics Corporate Presentation, April 2021
Slide 2: Forward-Looking Statements
Forward - Looking Statements 2 This presentation (“Presentation”) is provided by Immatics N . V . (“Immatics” or the “Company”) for informational purposes only . The information contained herein does not purport to be all - inclusive and Immatics nor any of its affiliates nor any of its or their con
Slide 3: Two Transformative Treatment Modalities: Adoptive Cell Therapies and TCR Bispecifics
Two Transformative Treatment Modalities: Adoptive Cell Therapies and TCR Bispecifics 3 Highly Differentiated Technologies to Identify True Cancer Targets and the Right TCRs Unlocking Immunotherapies for Solid Cancer Patients Strategic Collaborations with World - leading Industry Players
Slide 4: Limitations of Current Immunotherapies in Solid Cancer Patients
Limitations of Current Immunotherapies in Solid Cancer Patients … Driven by a Lack of Known Cancer - specific Targets 4 1 Chalmers et al. , 2017; 2 SEER Cancer Statistics Review, 1975 - 2017, Estimated New Cancer Cases for 2020 Checkpoint inhibitors mainly effective in tumors with high mutational bu
Slide 5: The Immatics Approach to Disrupt Current Tumor Treatment Paradigms
The Immatics Approach to Disrupt Current Tumor Treatment Paradigms Based on 5 Defined Principles 5 1. True Cancer Targets & Matching Right TCRs 2. Targeted Approach in Two Distinct Modalities: Adoptive Cell Therapy & TCR Bispecifics 3. Optimized Manufacturing to Enhance T cell Persistence & Efficacy
Slide 6: Immatics' Targeted Approach in Two Distinct Modalities
Immatics’ Targeted Approach in Two Distinct Modalities 6 High tumor burden Lower tumor burden 1 1 Patients at earlier stage of disease, de - bulked tumors, or late - stage patients with reduced tumor burden Specialized Centers All Hospitals & Out - Patient Intro
Slide 7: Immatics' Pipeline
Immatics ’ Pipeline 7 Modality Product Candidate Status Preclinical Phase 1a 1 Phase 1b 1 Phase 2 Phase 3 Autologous ACT ACTengine® IMA201 (MAGEA4/8) Proprietary ACTengine® IMA202 (MAGEA1) Proprietary ACTengine ® IMA203 (PRAME) Proprietary ACTengine® IMA204 (COL6A3) Proprietary ACT programs (Undiscl
Slide 8: Significant Addressable Solid Cancer Patient Populations
Significant Adressable Solid Cancer Patient Populations High Prevalence of MAGE4/8, MAGEA1 and PRAME in Major Tumor Indications 8 Niche Indications with Fast Track Development Potential Squamous NSCLC HNSCC ~23,500 HLA - A*02 + cases p.a. Uterine Carcinoma Ovarian Cancer 35% 50% ~23,500 HLA - A*02 +
Slide 9: Adoptive Cell Therapy
Adoptive Cell Therapy 9
Slide 10: Key Features of Our Clinical ACTengine Programs
IMA201 IMA202 IMA203 Peptide Target HLA - A*02 - presented peptide derived from MAGEA4/8 MAGEA1 PRAME shown to be naturally and specifically presented on native tumor tissues at d ifferentiated high peptide target density 1 100 - 1,000 copies/cell 50 - 900 copies/cell 100 - 1,000 copies/cell T cell
Slide 11: ACTengine Clinical Programs – Clinical Overview & Patient Flow
ACTengine ® Clinical Programs – Clinical Overview & Patient Flow 11 * Thereof 10 patients evaluable for biological activity and clinical efficacy analysis at data cut - off; * * D ose modifications of lymphodepletion regimen for certain risk groups (e.g. patients with HCC & patients with reduced ren
Slide 12: TEAEs by maximum severity
12 TEAEs by maximum severity ( N=16) Adverse event All Grades ≥ Grade 3 No . % No . % Patients with any adverse event 16 100.0 16 100.0 Lymphopenia 16 100.0 16 100.0 Leukopenia 16 100.0 16 100.0 Neutropenia 16 100.0 15 93.8 Anaemia 16 100.0 10 62.5 Thrombocytopenia 15 93.8 6 37.5 Nausea 11 68.8 0 0
Slide 13: ACTengine Clinical Programs – Biological Activity
ACTengine® Clinical Programs – Biological Activity T cells R obustly Engraft, Persist and Infiltrate into Tumor after Infusion of Low Doses of ACTengine® • Robust T cell engraftment and persistence post infusion until the end of the observation period as assessed by qPCR * • Engineered T cells are d
Slide 14: ACTengine Clinical Programs – Best Overall Response Assessment
ACTengine® Clinical Programs – Best Overall Response (BOR) Assessment Disease Control in 9 out of 10 Patients at Dose Level 1 and 2 (below 1 Billion Transduced CD8 T cells) IMA201 IMA202 IMA203 Patient 201 - DL1 - 01 202 - DL1 - 01 202 - DL1 - 02 202 - EC1 - 01 202 - DL2 - 01 202 - DL2 - 02 203 - DL
Slide 15: ACTengine Clinical Programs – Change of Sum of Diameters in Target Lesions
ACTengine ® Clinical Programs – Change of Sum of Diameters in Target Lesions Tumor Shrinkage Observed in 8 of 10 Patients at Low Dose Levels 15 1 Shortest diameter for nodal lesions; 2 Stable target lesions with parallel growth of a CNS non - target lesion ; 3 RECIST1.1 response at timepoint of maxi
Slide 16: ACTengine IMA204 – Targeting Tumor Stroma
ACTengine ® IMA204 – Targeting Tumor Stroma Complete Tumor Eradication in vitro & in vivo 1 by Affinity - enhanced IMA204 TCR Candidates One IMA204 TCR candidate leads to full functionality of both CD8 and CD4 T cells Control TCR2 Double mut. TCR1 Single mut. D7 D16 D22 D29 1 In vivo data by Jim Ril
Slide 17: Combating Tumor Heterogeneity & Escape through Multi-Target Approach
Combating Tumor Heterogeneity & Escape through Multi - Target Approach A Multi - Step Approach towards Highly Personalized Multi - TCR - T Therapy 17 ACTolog ® ACTengine ® TCR - T Personalized Multi - TCR - T 1 2 3 Combination Trial ACTengine ® Multi - TCR - T 4 >200 prioritized XPRESIDENT® targets
Slide 18: ACTengine IMA200 Series – Summary and Future Directions
ACTengine® IMA200 Series – Summary and Future Directions • IMA201, IMA202, IMA203 clinical trials • Complete Dose Escalation • Initiate Dose Expansion and treat patients at target dose • Update on patients treated at target dose expected for 2H2021 Next Steps 18 Transient and manageable treatment -
Slide 19: ACTallo IMA301 – Towards Off-the-shelf ACT
ACTallo® IMA301 – Towards Off - the - shelf ACT Effective Redirection of γδ T cells Using αβ TCR 19 • Proprietary manufacturing protocol delivering robust expansion of γδ T cells with the potential for hundreds of doses from one single donor leukapheresis • Off - the - shelf cell therapy , applicabl
Slide 20: TCR Bispecifics
aoe Immatics TCR Bispecifics
Slide 21: TCER – Immatics' TCR Bispecifics
TCER® – Immatics ’ TCR Bispecifics Off - the - shelf Biologics Linking Immune Cells to Tumor Cells 21 TCER®
Slide 22: TCER – Superior Proprietary TCR Bispecific Format
TCER® – Superior Proprietary TCR Bispecific Format 22 TCER® T cell recruiting antibody pHLA targeting TCR Fc domain (silenced) with KiH technology TCER® Potency and stability of proprietary TCER® format is superior to six alternative TCR Bispecific formats 1 1 Based on comparative preclinical testin
Slide 23: TCER – Preclinical POC for IMA401
TCER® – Preclinical POC for IMA401 IMA401 Targeting MAGEA4/8 Results in Tumor Eradication of Established Tumors 23 * TCER® Study day - 14: transplantation of tumor cells Study day 1: human PBMC transplantation & start of IMA401 weekly treatment Patient - Derived Tumor Model 2 Preclinical Proof - of
Slide 24: Advancing TCER IMA401 Towards Clinical Development
Advancing TCER® IMA401 Towards Clinical Development Recent Achievements and Intended Next Steps for IMA401 24 CMC x Manufacturing process development & pilot run completed x Formulation development completed » Next step: GMP run scheduled for 2Q2021 First - in - human clinical trial in patients with
Slide 25: Discovery Platforms
808 Immatics Discovery Platforms
Slide 26: XPRESIDENT – Discovery of True Cancer Targets
XPRESIDENT® – Discovery of True Cancer Targets Quantitative, Ultra - Sensitive Mass Spectrometry Expertise Developed over Two Decades >2,000 cancer & normal tissues a nalyzed by Quantitative, Ultra - Sensitive Mass Spectrometry Unbiased Identification & characterization of the most relevant 1 pHLA t
Slide 27: MAGEA4/8 Target in IMA201 and IMA401 Programs
MAGEA4/8 Target in IMA201 and IMA401 Programs Unique Target Discovery and Characterization Capabilities >5 - fold higher target density 1 than a commonly used MAGEA4 target peptide 27 MAGEA4/8 Peptide ( q uantitative mass spectrometry detection) Normal tissue Cancer tissue Status as of Oct 2020 Tech
Slide 28: Development of the Right TCR – XCEPTOR
Development of the Right TCR – XCEPTOR® Unique Cross - Talk between Target and TCR Discovery 28 TCR Bispecifics T cell engaging receptor (TCER®) Affinity - maturated natural TCR variable domains w ith nanomolar affinity and favorable specificity profile XPRESIDENT® - guided similar peptide counterse
Slide 29: Corporate Information & Milestones
Corporate Information & Milestones 29
Slide 30: Robust IP Portfolio
Robust IP Portfolio Immatics’ Patent Estate – Territorial Coverage 30 • >8,000 cancer targets, TCRs and technology protected by • 3,500 applications and patents filed in all major countries and regions • >100 patent families • >1,550 granted patents, thereof >400 granted patents in the US Corporate
Slide 31: Strong, Focused and Highly Integrated Trans-Atlantic Organization
Strong, Focused and Highly Integrated Trans - Atlantic Organization 31 Senior Leadership, Business Development, Intellectual Property, Regulatory Affairs, Communications Senior Leadership, Research and Development (Adoptive Cell Therapy), CMC, Clinical Operations, Regulatory Affairs, QA/QC, HR, Inve
Slide 32: Experienced Global Leadership Team Across Europe and the US
Experienced Global Leadership Team Across Europe and the US 32 Harpreet Singh Chief Executive Officer Co - Founder 20 yrs biotech experience Carsten Reinhardt Chief Development Officer >20 yrs pharma & biotech experience ( Micromet , Roche, Fresenius) Rainer Kramer Chief Business Officer 25 yrs phar
Slide 33: Upcoming R&D Milestones in 2021
Upcoming R&D Milestones in 2021 33 1H 2021 2H 2021 ACTengine ® IMA201, 202, 203: Initial Ph1a dose escalation read - out IMA201, 203: Additional Ph1a read - out IMA204: IND * submission TCER® IMA401: IND * submission IMA202: Initial Ph1b dose expansion read - out IMA402: Preclinical PoC & start GMP
Slide 34: Immatics Key Take-Aways
Immatics Key Take - Aways 34 • Broadly positioned in TCR therapeutics space with two distinct treatment modalities: ACT & TCR Bispecifics • ACTengine® (TCR - T) IMA200 Clinical Series • Proprietary cell manufacturing resulting in younger T cells for better engraftment & persistence • First anti - tu
Slide 35: Thank you
8oe immiatics yr DELIVERING THE POWER \ OF T CELLS TO CANCER PATIENTS j 7 ate F | Thank you ‘www.immatics.com in| ¥